Efficacy News and Research

RSS

CryoLife files PerClot IDE with FDA to initiate clinical trials in the U.S.

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that it has filed an IDE with the United States Food and Drug Administration to begin clinical trials for the purpose of obtaining Pre-Market Approval to distribute PerClot in the U.S. to control bleeding during surgical procedures or following traumatic injuries.

5 Apr 2011

Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results

ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

Cardioxyl Pharmaceuticals, Inc. announced today that it is presenting two abstracts from studies of its lead clinical candidate, CXL-1020, at the American College of Cardiology's 60th Annual Scientific Session & Expo in New Orleans, Louisiana.

5 Apr 2011

Caliper introduces novel fluorescent imaging agent for pre-clinical research

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the launch of XenoLight RediJect COX-2 Probe, a novel fluorescent imaging agent for pre-clinical research that specifically detects the cyclooxygenase-2 biomarker noninvasively in live animal models as well as in ex vivo tissue analysis applications.

5 Apr 2011

Pfizer receives FDA Refusal to File letter for tafamidis to treat Transthyretin Familial Amyloid Polyneuropathy

Pfizer Inc. announced today that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for tafamidis, the company's novel, oral investigational compound for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).

4 Apr 2011

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload technology, today disclosed the profile and first preclinical data for the Company's novel IMGN529 product candidate for the treatment of B-cell malignancies including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

4 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

Experts to discuss on healthcare-associated infection at SHEA Annual Meeting

A special media phone briefing with leading infectious disease scientists and healthcare-associated infection experts who will headline the 2011 Society for Healthcare Epidemiology of America's Annual Meeting

4 Apr 2011

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's market-leading XIENCE V Everolimus Eluting Coronary Stent System.

4 Apr 2011

BSX presents ION and TAXUS Stent trial data against coronary artery disease at ACC meeting

Boston Scientific Corporation today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favoring the next-generation ION Platinum Chromium Paclitaxel-Eluting Stent System compared to the currently available TAXUS Liberte Paclitaxel-Eluting Stent System.

4 Apr 2011

$FDA clears Vexim's COHESION bone cement to treat vertebral compression fractures$

FDA clears Vexim's COHESION bone cement to treat vertebral compression fractures

Vexim, the specialist in medical instruments designed for the minimally invasive, anatomical treatment of vertebral compression fractures, today announced that it had been awarded FDA clearance for its new product COHESION, a bone cement for injection into the vertebra following minimally invasive spinal fracture anatomical restoration with the company's SpineJack® device or used in performing a conventional vertebroplasty.

4 Apr 2011

Study finds increased carbapenem use in VA acute care health facilities over the last 5 years

A large, multi-year study of antibiotic use in Veterans Health Administration's acute care facilities demonstrates dramatically increased use of carbapenems, a powerful class of antibiotics, over the last five years.

4 Apr 2011

Positive results from GDC-0449 Phase II data against basal cell nevus syndrome

A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoagulation system REG1, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA.

4 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Series of new clinical trials confirm range of viable treatment options for HCV patients

Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.

2 Apr 2011

Rsearchers define new step that controls programmed cell death in cancer cells

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death.

2 Apr 2011

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death. In contrast to other stress-induced genes, which dispense with the regular transcriptional entourage, p21Cip1 still requires SKIP, a transcription elongation factor that also helps with the editing of transcripts, to be expressed, found researchers at the Salk Institute for Biological Studies.

2 Apr 2011

Champions enters exclusive license agreement with BCCA for Irinophore C

Champions Biotechnology, Inc. announced today that it has exercised an option to license Irinophore C, a liposomal formulation of Irinotecan, from the BC Cancer Agency in British Columbia, Canada.

2 Apr 2011

Efficacy News and Research

CryoLife files PerClot IDE with FDA to initiate clinical trials in the U.S.

Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

Caliper introduces novel fluorescent imaging agent for pre-clinical research

Pfizer receives FDA Refusal to File letter for tafamidis to treat Transthyretin Familial Amyloid Polyneuropathy

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Experts to discuss on healthcare-associated infection at SHEA Annual Meeting

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

BSX presents ION and TAXUS Stent trial data against coronary artery disease at ACC meeting

FDA clears Vexim's COHESION bone cement to treat vertebral compression fractures

Study finds increased carbapenem use in VA acute care health facilities over the last 5 years

Positive results from GDC-0449 Phase II data against basal cell nevus syndrome

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Series of new clinical trials confirm range of viable treatment options for HCV patients

Rsearchers define new step that controls programmed cell death in cancer cells

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

Champions enters exclusive license agreement with BCCA for Irinophore C

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News